Shares of Intellipharmaceutics (NASDAQ: IPCI) surged 172% today following a patent litigation settlement announcement after the market close on Thursday for a generic formulation of Focalin XR that is licensed to Par Pharma (NYSE: PRX). $IPCI is a component in both the HavRx Generic Drug and Regulatory Catalyst indexes and is awaiting a FDA decision along with $PRX for a pending ANDA for Dexmethylphenidate XR as a generic formulation of the ADHD drug Focalin XR.

mikehavRx.com Index Updates is a premium service that provides investors with time-saving information and updates on unique global baskets of stocks that are organized and managed within the 18 HavRx Stock Indexes outlined below that are being tracked at the Investars YOU website since June 2009. Please visit www.mikehavRx.com for more details on my new publishing company, website, and premium service.

Disclosure: No positions

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials. The HavRx Regulatory Catalyst Index update report is currently tracking over 600 events and 400 companies.

Click on the following email archive web link for a 50% discount promo code and for more details on the mikehavRx.com Personalized VIP service… http://eepurl.com/L7y1